New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:48 EDTLGND, ONXXLigand Pharma should benefit significantly from Onyx drug, says Roth Capital
After Onyx (ONXX) reported $18.6M in Kyprolis sales for Q3, Roth Capital notes that Ligand (LGND) receives a 3% average royalty on Kyprolis sales. The firm believes that Kyprolis will help enable Ligand to rapidly become profitable and it maintains a $25 target and Buy rating on the stock.
News For LGND;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
08:03 EDTLGNDLigand sees Q4 EPS 57c-62c, consensus $67c
Subscribe for More Information
08:02 EDTLGNDLigand still sees FY14 EPS $1.50-$1.55, consensus $1.54
Subscribe for More Information
08:01 EDTLGNDLigand reports Q3 EPS 36c, consensus 31c
Subscribe for More Information
October 23, 2014
09:23 EDTLGNDLigand price target raised to $121.50 from $92 at Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use